CN112237625A - 包含天然萃取物的女性清洁剂用组合物 - Google Patents
包含天然萃取物的女性清洁剂用组合物 Download PDFInfo
- Publication number
- CN112237625A CN112237625A CN202010206229.6A CN202010206229A CN112237625A CN 112237625 A CN112237625 A CN 112237625A CN 202010206229 A CN202010206229 A CN 202010206229A CN 112237625 A CN112237625 A CN 112237625A
- Authority
- CN
- China
- Prior art keywords
- composition
- extract
- vitamin
- vaginal
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 239000000284 extract Substances 0.000 title claims abstract description 82
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 23
- 229940088594 vitamin Drugs 0.000 claims abstract description 15
- 229930003231 vitamin Natural products 0.000 claims abstract description 15
- 235000013343 vitamin Nutrition 0.000 claims abstract description 15
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 241000241413 Propolis Species 0.000 claims abstract description 13
- 229940069949 propolis Drugs 0.000 claims abstract description 13
- 229920001661 Chitosan Polymers 0.000 claims abstract description 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 10
- 108010035532 Collagen Proteins 0.000 claims abstract description 10
- 229920001436 collagen Polymers 0.000 claims abstract description 10
- 241001480003 Chaetothyriales Species 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 229940107702 grapefruit seed extract Drugs 0.000 claims abstract description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 5
- 244000061520 Angelica archangelica Species 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 210000001215 vagina Anatomy 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 241000222122 Candida albicans Species 0.000 claims description 23
- 229940095731 candida albicans Drugs 0.000 claims description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 241000213006 Angelica dahurica Species 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229940044977 vaginal tablet Drugs 0.000 claims description 5
- 239000000003 vaginal tablet Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 206010051873 Vaginal relaxation Diseases 0.000 claims description 4
- 229930003451 Vitamin B1 Natural products 0.000 claims description 4
- 229930003471 Vitamin B2 Natural products 0.000 claims description 4
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 235000010374 vitamin B1 Nutrition 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 235000019164 vitamin B2 Nutrition 0.000 claims description 4
- 239000011716 vitamin B2 Substances 0.000 claims description 4
- 239000011726 vitamin B6 Substances 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 241000167550 Centella Species 0.000 claims 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000007794 irritation Effects 0.000 abstract description 10
- 229940059958 centella asiatica extract Drugs 0.000 abstract description 7
- 208000013464 vaginal disease Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 23
- 206010046914 Vaginal infection Diseases 0.000 description 16
- 201000008100 Vaginitis Diseases 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 208000003251 Pruritus Diseases 0.000 description 13
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 241000434018 Euphorbia pekinensis Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 229960000913 crospovidone Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical group OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 4
- 241000382455 Angelica sinensis Species 0.000 description 4
- 241000222178 Candida tropicalis Species 0.000 description 4
- 244000146462 Centella asiatica Species 0.000 description 4
- 235000004032 Centella asiatica Nutrition 0.000 description 4
- 241000221079 Euphorbia <genus> Species 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 241000222126 [Candida] glabrata Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 4
- 208000032343 candida glabrata infection Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003905 vulva Anatomy 0.000 description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000125175 Angelica Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010006784 Burning sensation Diseases 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 3
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 3
- 229940022757 asiaticoside Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000003433 contraceptive agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229960004130 itraconazole Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010060937 Amniotic cavity infection Diseases 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 208000008158 Chorioamnionitis Diseases 0.000 description 2
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- 241000207201 Gardnerella vaginalis Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 208000037009 Vaginitis bacterial Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- AGABNGOXUSXQDD-XKGFZTIGSA-N [(3s)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C(\C)=C/C)C(C)(C)OC1=C2 AGABNGOXUSXQDD-XKGFZTIGSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 2
- 229940011658 asiatic acid Drugs 0.000 description 2
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 description 2
- AGABNGOXUSXQDD-UHFFFAOYSA-N decursinol angelate Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C(C)=CC)C(C)(C)OC1=C2 AGABNGOXUSXQDD-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 208000010484 vulvovaginitis Diseases 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 241000223678 Aureobasidium pullulans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000577922 Dystaenia takesimana Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 241000206755 Palmaria Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010036603 Premature rupture of membranes Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000005382 Saccharum spontaneum Species 0.000 description 1
- 241001091465 Sempervivum Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000009188 angelicae sinensis extract Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
Abstract
本发明涉及包含天然萃取物的女性清洁剂用组合物,本发明的包含天然萃取物的女性清洁剂用组合物包含:蜂胶、胶原蛋白肽、黑酵母、壳聚糖、选自由当归萃取物、积雪草萃取物、西柚籽萃取物及其混合物构成的组中的天然萃取物;及水溶性维生素。该组合物的预防及治疗阴道相关疾病的效果优异,同时,包含天然萃取物,使用时几乎没有刺激,能够提供更健康的环境且抗菌活性优异。
Description
技术领域
本发明涉及包含天然萃取物的女性清洁剂用组合物。更具体地,涉及一种将天然萃取物作为主要成分包含其中的用于预防及治疗女性的阴道相关疾病的女性清洁剂用组合物。
背景技术
女性的阴道是外阴部和子宫的连接通路,是女性身体中湿气最多且温暖的地方。由于环境适合作为阴道炎主要原因的细菌和霉菌栖息,因此由此引发疾病的可能性很大。在正常条件下,阴道内部栖息有大量的乳酸菌,以使阴道内部处在弱酸性,从而抑制病原菌或霉菌增殖,但由于长期服用抗生素或避孕药、使用卫生棉条或避孕环、或怀孕或分娩、哺乳、绝经等导致女性荷尔蒙的平衡变化等,破坏了阴道内部的平衡时,会发生在阴道内正常条件下通常抑制生长的机会性感染病原体的增殖,从而会导致阴道炎的发病。据报道,阴道炎有细菌性阴道炎(bacterial vaginosis)、念珠菌阴道炎(Candida vaginitis)、滴虫性阴道炎(Trichomonas vaginitis)、萎缩性阴道炎(Atrophic vaginitis)等。
最常见的疾病是细菌性阴道炎(Bacterial vaginosis),由阴道加特纳菌(Gardnerella vaginalis)引起发病。该阴道炎是由于阴道内酸度的不平衡,栖息在阴道内的乳酸菌减少,而低于1%的厌氧细菌过度增殖而发生的。关于引起正常阴道菌群变化的诱发因子尚未公布,但推断是由于频繁的性交或清洗阴道引起的阴道反复的碱化所引起。应正常存在并且生成过氧化氢的乳酸菌消失时,难以再生正常阴道菌群,因此会经常发生细菌性阴道炎的复发。
另外,患有细菌性阴道炎的女性发生盆腔炎(Pelvic inflammatory disease,PID)、流产后PID、子宫切除术后切口蜂窝织炎(postoperative cuff cellulitis)、宫颈细胞异常等严重后遗症的频率提高,且孕产妇存在胎膜早破、早期阵痛、早产、绒膜羊膜炎(chorioamnionitis)、剖腹产术后的子宫内膜炎等的危险。
作为如细菌性阴道炎一样常见的疾病,念珠菌阴道炎(Candida vaginitis)是作为真菌的白色念珠球菌(Candida albicans)栖息在湿潮的阴部并引起炎症的疾病,约75%的女性在一生中会经历一次以上的阴道和外阴部的念珠菌阴道炎,且45%的女性1年复发2次以上。当正常地存活在健康人的口腔、肠道、阴道等的念珠菌(主要是白色念珠球菌)因怀孕或长期服用口服避孕药等,导致女性荷尔蒙的状态异常,或因感冒或糖尿病、艾滋等原因,免疫力极度衰弱时,会诱发感染。还可能因服用了用作肥胖、抗生素的过敏或关节炎等的治疗剂的肾上腺皮质激素等而发病。因抗生素的给药而引起发病,是因抗生素杀死阴道内的有益乳酸菌而发生,这种情况下,复发的可能性也较大。穿戴过紧的腰带或裤子等通风不顺畅的情形或洗澡后未擦干外阴部的水分的情况下穿潮湿内裤的情形、经期卫生巾更换不及时的情形下也容易发病。阴道内栖息有白色念珠球菌的女性中,仅50%有症状,主要症状是白带增多、皮肤产生炎症反应而瘙痒,根据病的种类和程度或2次细菌感染等,具有皮肤蜕皮或化脓等的差异。特征性的症状有出现白色浓稠的分泌物,且外阴部神经非常敏感,会感到疼痛,有时会产生浮肿和炎症。具有灼热感、性交痛、浮肿、外阴部疼痛等,临床表现包括外阴部及阴道的红斑、充血、表皮脱落、囊泡、脓疱等。
为了预防如上所述的女性疾病,使用清洁剂(阴道清洗剂)、外阴部清洗剂的情形较多。为了预防阴道炎,通常所使用的局部清洗剂上市的有,磺化脂肪酸或经蒸馏的月桂醇(lauryl alcohol)等,并混合镇静剂、增稠剂、营养剂、发泡剂、有机杀菌剂等的透明或乳液(lotion)类型。另外,还有以具有清洁力的表面活性剂及作为医药品的聚维酮碘为主要成分。已知,所述经化学合成的消毒剂聚维酮碘,对预防及治疗念珠菌阴道炎、毛滴虫阴道炎及其他阴道感染炎症具有功效,但可能会引起碘等的过敏症状或因粘膜损伤导致的瘙痒感、灼热感、皮肤溃疡、接触性皮肤炎等,阴道内无机碘或血液中总碘数值上升,会诱发甲状腺功能减退。
用于消除如上所述的使用作为医药品的消毒剂引起的副作用的现有技术,基于健康女性通过阴道内有益微生物的乳酸分泌,将阴道内酸度保持在pH3.2,在这种低酸度下,会抑制增殖或杀灭大部分的有害菌,提出以乳酸为主要成分并且添加在牛奶中萃取的乳清(lactoserum)的pH3.5的缓冲溶液制剂,但是,与其将其称为女性用清洁剂,不如说是一种将阴道内pH保持在正常状态的阴道内适宜酸度保持剂,难以期待根本性的治疗和预防效果。
因此,需要开发一种女性清洁剂,其作为能够有效预防上述女性的阴道相关疾病,能够将阴道内pH保持在正常状态,由于刺激性低,使用容易的女性清洁剂或外阴部清洗剂,包含了天然功能成分,使用时能够提供更健康的环境。
现有技术文献
专利文献
专利文献1:KR 10-2015-0148530 B1
发明内容
发明要解决的问题
本发明的目的在于,提供一种对预防或治疗女性相关疾病有效的包含天然萃取物的女性清洁剂用组合物。
本发明的另一目的在于,提供一种女性清洁剂用组合物,其预防及治疗阴道相关疾病的效果优异,同时,包含天然萃取物,使用时几乎没有刺激,能够提供更健康的环境,且抗菌活性优异。
用于解决问题的手段
为了实现所述目的,本发明的一实施例的包含天然萃取物的女性清洁剂用组合物包含:蜂胶、胶原蛋白肽、黑酵母、壳聚糖、选自由当归萃取物、积雪草萃取物、西柚籽萃取物及其混合物构成的组中的天然萃取物;及水溶性维生素。
所述组合物用于预防或治疗阴道相关疾病,所述阴道相关疾病包括阴道松弛、阴道干涩、阴道真菌及带下病。
所述组合物对作为真菌类的白色念珠菌(Candida albicans)具有抗菌活性效果。
所述水溶性维生素包含选自由维生素C、维生素B1、维生素B2、烟酸、维生素B6、维生素B12、叶酸及生物素构成的组。
所述组合物进一步包含其他添加剂,所述其他添加剂是赋形剂、崩解剂及润滑剂。
所述组合物是清洗组合物或阴道片。
所述组合物进一步包含第二天然萃取物,所述第二天然萃取物选自由白芷萃取物、Seombadi萃取物及其混合物构成的组。
以下,进一步详细说明本发明。
本说明书中所使用的术语“萃取物”如上所述,具有在本领域中以粗提物(crudeextract)通用的含义,广义上还包含对萃取物进一步分级(fractionation)的级分。即,萃取物不仅包含上述的利用萃取溶剂获得的,还包含在这基础上进一步应用纯化过程而获得的。例如,使所述萃取物通过具有恒定分子量截留值的超滤膜而获得的分馏物、通过各种色谱法(为了根据大小、电荷、疏水性或亲和力进行分离而制作)进行的分离等通过进一步实施的多种纯化方法而获得的分馏物也包含在本发明的萃取物中。
包含本发明的一实施例的天然萃取物的女性清洁剂用组合物包含蜂胶、胶原蛋白肽、黑酵母、壳聚糖、选自由当归萃取物、积雪草萃取物、西柚籽萃取物及其混合物构成的组的天然萃取物、及水溶性维生素。
所述蜂胶(Propolis)是蜜蜂从树芽或树液等植物中收集的树脂的混合物,是天然抗菌物质。具有抗菌、杀菌作用和激活免疫力、免疫功能增强作用、细胞活化及细胞再生作用、抗过敏作用、防御基因损伤作用、强化血管作用、抗氧化作用、抗癌剂副作用减轻作用等。另外,蜂胶还起到调节症状的作用。
所述蜂胶是为了抗菌、抗炎及抗氧化效果而包含其中,天然萃取物是为了缓解皮肤问题、保湿、皮肤柔韧性、皮肤弹力、皮肤再生、改善血液循环及镇定敏感性皮肤等而包含其中。
即,通过将蜂胶包含在女性清洁剂用组合物中,能够表现出用于预防或治疗阴道相关疾病的抗菌、抗炎及抗氧化效果,但可能由此导致对皮肤产生刺激的问题,本发明将通过进一步包含天然萃取物来解决这种问题。
黑酵母(Aureobasidium pullulans)含有大量贝塔葡聚糖,已知对保湿、弹力、过敏性皮肤瘙痒的效果优异。所述贝塔葡聚糖构成酵母的细胞壁,作为起到天然保湿因子作用的氨基酸在提供保湿的同时增加弹性,并且由于皮肤亲和力优异,因此能够增加免疫力。
壳聚糖(Chitosan)是一种经过加工的物质,使人体吸收甲壳类中所含的几丁质,具有排出体内重金属及污染物质等的效果,并且具有优异的抗菌效果及能够增加保湿效果。
已知,所述当归具有多种药理学效果,代表性的有治疗贫血、镇定作用、镇痛效果、滋补品、治疗痛经、治疗更年期综合征、治疗腹痛、治疗伤口、治疗关节炎、治疗糖尿性高血压。已知当归中存在香豆素类多种物质,代表性的有前胡素(decursin)和紫花前胡醇当归酯(decursinol angelate),且大量包含,这在很久前(1967年)就已有报道,近期还报道了二氢吡喃香豆素(dihydropyrano coumarin)系列的物质具有抗癌效果。
所述积雪草(centella asiatica extract)起源于印度洋的热带地区,是在阴湿的海拔600米完全自然生长的植物,还被称为雷公根(gotu kola)、印度石莲花(indianpennywork)或棕叶草(tiger grass)。这种积雪草中含有称为三萜(Triterpenoids)(皂苷)的积雪草苷(asiaticoside)、积雪草甙(madecasosside)、积雪草酸(asiatic acid)及羟基积雪草酸(madecassic acid)成分,已知它们起到调节及促进人体的胶原蛋白的合成作用,强化血管以促进血液循环,且有助于提高记忆力。
西柚籽(Grapefruits Seed)是从西柚籽中萃取的天然抗氧化剂,是天然的杀菌、消毒、防腐剂,在医学上,对于病菌或细菌感染用作内服药,对于伤口或中耳炎、咽喉炎等用作外用药。另外,对细菌和霉菌等的腐败性及病原性微生物具有强力的杀菌效果。
相对于整体重量,可以分别以0.1至1.5重量%包含所述黑酵母、壳聚糖、当归萃取物、积雪草萃取物及西柚籽萃取物,并且不局限于所述示例。
所述天然萃取物指能够由本领域技术人员以常规的萃取方法萃取出的萃取物,萃取物可以为粉末形式,不局限于所述示例。
所述组合物用于预防或治疗阴道相关疾病,所述阴道相关疾病包括阴道松弛、阴道干涩、阴道真菌及带下病。
所述阴道相关疾病是指以阴道分泌物、气味、灼热感、瘙痒感、性交痛、排尿痛等症状为特征的阴道的感染或炎症状态。
阴道松弛是阴道周围的肌肉和阴道入口肌肉松弛,阴道粘膜减少,从而使筋膜松弛的症状,由于阴道的弹力下降,因此性快感变弱、发生性关系时会具有性冷淡,在严重的情况下,可能会导致缺乏作为女性的自信。
阴道干涩是因爱液不足的体质或子宫和阴道周边的血流量和血液循环减少导致的应正常分泌的阴道分泌液减少的现象,女性荷尔蒙减少时,失去弹性和柔韧性的阴道和尿道系统的上皮细胞变薄的同时主要发生。如果持续长时间的阴道干涩时,会导致免疫力降低,会暴露在各种疾病中,收缩力减退导致的尿失禁、子宫脱位等危险紧随其后。
阴道真菌是由念珠菌引起的阴道炎,是念珠菌栖息在潮湿的阴部并诱发炎症的最常见的阴道炎之一。主要症状是白带增多、皮肤出现炎症反应而感到瘙痒。另外,根据病的种类和程度或2次细菌感染等,存在皮肤蜕皮或化脓等的差异。
带下病是整个身体或身体的一部分的血液循环不顺畅而产生的一种循环障碍,症状是女性的性器官所分泌的分泌物白带的量增多。出现这种分泌物的原因在于,保护生殖器免受各种有害细菌侵害的自然现象,但是当该分泌物的量增加时,粘附在内衣上的现象严重,由于量多且常常持续潮湿的状态,会产生气味,并且容易招致作为阴道炎的最常见的致病菌白色念珠球菌(candida albicans)中。
本发明是用于预防及治疗上述疾病的,可用于阴道相关疾病的预防及治疗全部,并且不局限于所述示例。
所述组合物包括对作为真菌类的白色念珠菌(Candida albicans)具有抗菌活性效果。
所述真菌类包含白色念珠球菌(Candida albicans)、热带念珠菌(Candidantropicalis)及光滑念珠菌(Candida glabrata)等,其中,白色念珠球菌(Candidaalbicans)是阴道炎的最常见的致病菌,占85-90%左右。
然而,由于除白色念珠球菌以外的念珠菌引起的外阴阴道炎的发病率正逐渐增加,念珠菌除了在阴道,还存在于口腔、支气管、肠道等,在健康的身体中也很常见,因此需要对所述真菌类具有抗菌活性效果的组合物。
优选地,所述抗菌活性是阻止或抑制作为真菌类的白色念珠球菌(Candidaalbicans)、热带念珠菌(Candidan tropicalis)及光滑念珠菌(Candida glabrata)的生长和存活功能的,对阴道炎的致病菌进行杀灭。
所述水溶性维生素包含选自由维生素C、维生素B1、维生素B2、烟酸、维生素B6、维生素B12、叶酸及生物素构成的组。
所述水溶性维生素可选自由维生素C、维生素B1、维生素B2、烟酸、维生素B6、维生素B12、叶酸及生物素构成的组中选择,优选为维生素C,即,以包含抗坏血酸为特征,但不局限于示例。
所述水溶性维生素优选包含抗坏血酸是为了将阴道内pH保持在弱酸性,以起到抗炎效果。通常,为了将阴道内的pH保持在弱酸性,女性清洁剂用组合物使用了钠盐、乳酸缓冲溶液等。这是为了使阴道内的pH保持在弱酸性而添加的成分,但在本发明中的抗坏血酸在保持阴道内的弱酸性环境的同时,能够表现出抗氧化效果、皮肤组织的生长和恢复、防止致癌物质生成等效果。
所述组合物还附加包含其他添加剂,所述其他添加剂包含赋形剂、崩解剂及润滑剂。
所述赋形剂选自由硅化微晶纤维素、淀粉、微晶纤维素、甘露醇、乳糖、低取代羟丙基纤维素、三氯蔗糖及其混合物构成的组,具体地,可包含硅化微晶纤维素(SMCC90)、淀粉(Starch1500)、微晶纤维素(微晶纤维素PH102)及甘露醇(甘露醇160C),但不局限于所述示例。
所述崩解剂可选自由交联聚维酮、淀粉葡萄糖酸钠、交联羧甲基纤维素钠、聚山梨酯、月桂基硫酸钠及其混合物构成的组,更具体为交联聚维酮(交联聚维酮CL-SF),但不局限于所述示例。
所述润滑剂可选自由硬脂酸镁、轻质无水硅酸、滑石粉、山萮酸甘油酯及其混合物构成的组,更具体为硬脂酸镁,但不局限于所述示例。
优选地,本发明的一实施例的女性清洁剂用组合物可包含0.2至3.0重量%的蜂胶、0.1至1.5重量%的胶原蛋白肽、0.1至1.5重量%的黑酵母、0.1至1.5重量%的壳聚糖、0.1至1.5重量%的当归萃取物、0.1至1.5重量%的积雪草萃取物、0.1至1.5重量%的西柚籽萃取物、0.5至5重量%的水溶性维生素、15至30重量%的硅化微晶纤维素、15至30重量%的淀粉、10至20重量%的微晶纤维素、20至40重量%的甘露醇、1至10重量%的交联聚维酮及0.5至5重量%的硬脂酸镁。
所述女性清洁剂用组合物包含低于0.2重量%的蜂胶时,会产生抗菌、抗炎及抗氧化效果微弱的问题,当超过3.0重量%时,会产生皮疹及呼吸困难等问题。
相对于整体重量,包含低于0.1重量%的所述胶原蛋白肽时,存在增进弹力及皮肤再生效果微弱的问题,超过1.5重量%时,会引发痤疮的产生及过敏反应的问题。
因此,在所述范围内作为女性清洁剂用组合物使用时,能够提供用于预防或治疗阴道相关疾病的保湿、皮肤弹力、抗菌及抗真菌效果优异的女性清洁剂用组合物。
所述组合物是清洗组合物或阴道片。
本发明作为女性清洁剂用组合物,所述剂型可以是用于胃肠道外给药的制剂,作为一实施例,可以是液剂、凝胶(gel)剂、清洗组合物、阴道片、栓剂形式、膏状、软膏、敷料溶液、喷雾剂、其他涂敷剂等的局部给药剂、溶液型、悬浮型、乳剂型等的液状剂型,可以包含灭菌的水溶液、非水性溶剂、悬浮剂、乳剂、冻干制剂、栓剂、膏、软膏、冻胶、泡沫、洗涤剂或阴道插入物,优选液剂、凝胶(gel)剂、清洗组合物、阴道片等的皮肤外用剂。
所述剂型作为一例,所述剂型可在灭菌水中添加助溶剂、乳化剂、用于调节pH的缓冲剂等来制备。所述非水溶剂或悬浮剂可使用如丙二醇(propylene glycol)、聚乙二醇(polyethylene glycol)、橄榄油等植物油,如油酸乙酯等可注射的酯类等。
所述栓剂可使用witepsol、聚乙二醇、吐温61(tween 61)、可可脂、月桂酸脂、甘油、明胶等。更具体地,所述女性清洁剂用组合物可包含加入到所述抗菌组合物以将其剂型化的载体。所述载体可使用粘合剂、润滑剂、悬浮剂、增溶剂、缓冲剂、防腐剂、润滑剂,等渗剂、稳定剂、分散剂、助悬剂、色素、香料等。
本发明的一实施例的女性清洁剂用组合物的优选给药量根据患者的状态及体重、疾病的程度、药物形式、给药途径及期间不同,但可由专业技术人员适当地选择。
本发明的一实施例的女性清洁剂用组合物的给药量可考虑到给药方法、服用者的年龄、性别及体重、及疾病的严重程度,由专业技术人员适当地选择。作为一实施例,以组合物为基准时,可以为0.0001mg/kg至1000mg/kg,为了更加有效,可以以0.01mg/kg至100mg/kg进行给药。就给药而言,可每天给药一次,或可以分数次进行给药。所述给药量在任何方面都不限制本发明的范围。
另外,本发明的一实施例的女性清洁剂用组合物除抗菌组合物之外,还可包含公知的具有阴道相关疾病的化合物或天然萃取物。
本发明的一实施例的女性清洁剂用组合物可直接用于包括人在内的动物。所述动物是指,对应于植物的生物群,主要以有机物为营养成分进行摄入,且消化或排泄及呼吸器官分化,详细而言,是脊椎动物,更详细而言,是哺乳类。所述哺乳类可以详细地为人。
所述组合物进一步包含第二天然萃取物,所述第二天然萃取物选自由白芷萃取物、Seombadi萃取物、大戟萃取物及其混合物构成的组。
优选地,本发明的女性清洁剂用组合物除所述天然萃取物之外,还进一步包含选自由白芷萃取物、Seombadi萃取物、大戟萃取物及其混合物构成的组中的萃取物。
白芷(Angelica dahurica BENTH)是双子叶植物伞形目伞形科的两年生或三年生草本,根茎粗壮,茎直立分枝,长到约1.5m左右的高度。叶子呈羽状,分开两次,分开的叶片呈椭圆形或披针形,末端尖锐,边缘不均匀地分开或呈锯齿状。分布在全国各地,生长在山区的溪流等水气重的地方。具有镇痛、消肿的功效,适用疾病有头痛、偏头痛、各种神经痛、牙痛、腹痛等。
Seombadi(Dystaenia takesimana(NAK.)KITAGAWA.)是双子叶植物伞形目伞形科的多年生草本,是一种在郁陵岛全域生长的多年生草本,由于猪比较爱吃,因此在郁陵岛中还称为猪草。是一种多年生植物,高度可达2m左右,有4至5个节。茎是空心的,叶子是交错的。叶柄长,基部宽,从而包裹主茎。中医里,根用作草药,对清热、解毒、散风、消痰、下气等有效。
所述大戟(Euphorbia pekinensis Rupr.)是生长在山上的多年生草本,高度达80cm,根部粗壮且生长笔直。叶子互生,是钝头或锐头且倒锥形,背面泛白色,边缘有细齿。花为绿黄色,在6月长在主茎末端。果实是蒴果,类似于疣的突起,种子为宽椭圆形,外部平坦。
随着进一步包含所述白芷萃取物、Seombadi萃取物及大戟萃取物,借助各成分间的混合作用,可提高用于预防或治疗阴道相关疾病的保湿、皮肤弹力、抗菌及抗真菌效果。
另外,复合使用所述天然萃取物时,能够起到用于预防或治疗的阴道相关疾病的优异的保湿、皮肤弹力、抗菌及抗真菌效果的同时,能够通过天然萃取物提供几乎没有刺激的女性清洁剂用组合物。
优选地,本发明的一实施例的女性清洁剂用组合物可包含0.2至3.0重量%的蜂胶、0.1至1.5重量%的胶原蛋白肽、0.1至1.5重量%的白芷萃取物、0.1至1.5重量%的Seombadi萃取物、0.1至1.5重量%的大戟萃取物、0.1至1.5重量%的黑酵母、0.1至1.5重量%的壳聚糖、0.1至1.5重量%的当归萃取物、0.1至1.5重量%的积雪草萃取物、0.1至1.5重量%的西柚籽萃取物、0.5至5重量%的水溶性维生素、15至30重量%的硅化微晶纤维素、15至30重量%的淀粉、10至20重量%的微晶纤维素、20至40重量%的甘露醇、1至10重量%的交联聚维酮及0.5至5重量%的硬脂酸镁。
发明效果
根据包含本发明的天然萃取物的女性清洁剂用组合物,能够起到预防或治疗阴道相关疾病的效果的同时,通过包含天然萃取物,使用时几乎没有刺激,能够提供更健康的环境。
附图说明
图1是关于将本发明的一实施例的女性清洁剂用组合物溶于纯净水后检测的pH结果的照片。
图2是关于本发明的一实施例的女性清洁剂用组合物的保湿效果的实验结果。
具体实施方式
以下,对本发明的实施例进行详细的说明,以使本发明所属技术领域的普通技术人员易于实施。然而,本发明可以由各种不同的形式来实现,不限于本文说明的实施例。
[制备例:女性清洁剂用组合物的制备]
1.女性清洁剂用组合物的制备
用搅拌机粉碎蜂胶、胶原蛋白肽、黑酵母、壳聚糖、当归萃取物、积雪草萃取物及西柚籽萃取物,将其用30目(mesh)筛过筛,以制备第一混合物,并将作为赋形剂的SMCC90、淀粉Starch1500、微晶纤维素PH102、甘露醇160C、作为水溶性维生素的抗坏血酸、作为崩解剂的交联聚维酮CL-SF放入30目筛中过筛,以制备第二混合物。
混合经制备的所述第一混合物和所述第二混合物,并加入0.89重量%的作为润滑剂的硬脂酸镁,混合并压片,以制备女性清洁剂用组合物。
按照如下表1所示的更具体的含量进行制备。
【表1】
(单位:重量%,25.56重量%的作为赋形剂的SMCC90、14.84重量%的微晶纤维素PH102、29.67重量%的甘露醇160C、1.13重量%的作为水溶性维生素的抗坏血酸、4.45重量%的作为崩解剂的交联聚维酮CL-S、剩余的淀粉Starch1500)
2.包含第二天然萃取物的女性清洁剂用组合物
利用与所述女性清洁剂用组合物(IV2)的制备方法相同的成分含量及制备方法,进一步添加作为第二天然萃取物的白芷萃取物、Seombadi萃取物及大戟萃取物,按照如下表2所述的具体含量来制备女性清洁剂用组合物。
【表2】
实验编号 | 白芷萃取物 | Seombadi萃取物 | 大戟萃取物 |
IT 1 | 0.05 | 0.05 | 0.05 |
IT 2 | 0.3 | 0.3 | 0.3 |
IT 3 | 0.5 | 0.5 | 0.5 |
IT 4 | 1 | 1 | 1 |
IT 5 | 1.5 | 1.5 | 1.5 |
IT 6 | 2 | 2 | 2 |
(单位:重量%)
[实验例1:对白色念珠球菌的抗菌力评价]
将各100μl的预培养的白色念珠球菌(Candida albicans)分装到纸片扩散法检测用平板培养基(沙氏葡萄糖琼脂(Sabouraud Dextrose Agar.Difco.USA))上并涂抹后,将所制备的所述实验编号IV1至10及IT1至6的女性清洁剂用组合物,以5mg/纸片的浓度在纸碟中滴在样品后,放在培养基上。
作为其对照组,将作为抗真菌剂的伊曲康唑(Itraconazol),以100μg/纸片的浓度在纸片中滴在样品后,放在培养基上。在28℃下培养该平板培养基48小时后,检测生长抑制区(Clean Zone:洁净区)的大小。在表3中示出其结果。
如下表3所示,本发明的女性清洁剂用组合物相比于作为对照组的伊曲康唑(抗真菌剂,专利10-0592066),表现出很强的生长抑制效果。
【表3】
如所述表3所示,确认了在进一步包含白芷萃取物、Seombadi萃取物及大戟萃取物的IT1至IT6中,生长抑制区(Clean Zone:洁净区)的大小减少效果优异,IT3至IT6中,表现出最为优异的生长抑制区(Clean Zone:洁净区)的大小减少效果。
因此,确认了本发明的女性清洁剂用组合物对白色念珠球菌(Candida albicans)具有很强的抗菌力。
[实验例2:瘙痒减少效果实验]
选择80人感到瘙痒的20岁~40岁的女性,并分为16组,每组5人,让她们使用在水中稀释的实验编号IV1至10及IT1至6的女性清洁剂用组合物10天后,评价防止瘙痒效果,并在表4中示出其结果。分数是10分至1分,分数越高表示防止瘙痒效果越优异。
【表4】
如所述表4所示,确认了进一步包含白芷萃取物、Seombadi萃取物及大戟萃取物的IT1至IT6中减少瘙痒效果优异,IT3至IT6中表现出最为优异的减少瘙痒效果。
[实验例3:皮肤刺激产生实验]
对于与实验例2相同的16个组,除防瘙痒效果以外,还进行了关于是否产生刺激的问卷调差,其结果如下表5及表6。
[评价标准]
◎:完全没有刺激
○:几乎没有刺激
△:稍微有刺激,尽量避免用于敏感的粘膜
Х:刺激严重,无法使用
【表5】
IV 1 | IV 2 | IV 3 | IV 4 | IV 5 | IV 6 | IV 7 | IV 8 | IV 9 | IV 10 | |
1 | ○ | ○ | ○ | △ | ○ | △ | △ | Х | Х | △ |
2 | ○ | ○ | ○ | ○ | ○ | Х | Х | Х | △ | Х |
3 | ○ | ○ | ○ | △ | ○ | Х | △ | Х | Х | Х |
4 | ○ | ○ | ○ | ○ | ○ | △ | △ | △ | Х | Х |
5 | △ | ○ | ◎ | ○ | ◎ | △ | Х | Х | Х | △ |
【表6】
根据所述表5及6,就IV1至5而言,得到了几乎没有皮肤刺激的评价,相反,IV6及IV10产生皮肤刺激。
就IT1至IT6而言,整体得到皮肤刺激不严重的评价,IT3及IT4得到了最为优秀的评价。
[实验例4:保湿性评价]
对于与实验例2相同的16个组,除是否产生刺激以外,还进行了关于保湿性的问卷调查,并在如下图2示出其结果。
如下图2所示,确认了在进一步包含白芷萃取物、Seombadi萃取物及大戟萃取物的IT1至IT6中保湿性能优异,在IT3至IT6中表现出最为优异的保湿效果。
[实验例5:清洁力评价]
对于与实验例2相同的16个组,除防瘙痒效果以外,还进行了关于作为女性清洁剂使用时的清洁力、清洁感、香味的问卷调查,其结果如下表7及8。
分数为10分至1分,分数越高,表示清洁力、清洁感、香味及综合偏好度越优异。
【表7】
【表8】
根据所述表7及表8,IV1至IV3及IV5在清洁力、清洁感、香味及综合偏好度方面得到了优秀的评价,其中,IV2、IV3及IV5得到了最为优秀的评价。
另外,就加入白芷萃取物、Seombadi萃取物及大戟萃取的女性清洁剂用组合物而言,整体得到了优秀的评价,尤其IT3及IT4得到了最为优秀的评价。
以上,对本发明的优选实施例进行了详细说明,但本发明的权利范围不限于此,利用权利要求书中所定义的本发明的基本概念的本领域技术人员的各种变形及改良形式均属于本发明的权利范围。
Claims (7)
1.一种女性清洁剂用组合物,其中,包含:
蜂胶;
胶原蛋白肽;
黑酵母;
壳聚糖;
天然萃取物,选自由当归萃取物、积雪草萃取物、西柚籽萃取物及其混合物构成的组;及
水溶性维生素。
2.根据权利要求1所述的女性清洁剂用组合物,其中,
所述组合物用于预防或治疗阴道相关疾病,所述阴道相关疾病是阴道松弛、阴道干涩、阴道真菌症及带下病。
3.根据权利要求1所述的女性清洁剂用组合物,其中,
所述组合物对作为真菌类的白色念珠菌具有抗菌活性。
4.根据权利要求1所述的女性清洁剂用组合物,其中,
所述水溶性维生素选自由维生素C、维生素B1、维生素B2、烟酸、维生素B6、维生素B12、叶酸及生物素构成的组。
5.根据权利要求1所述的女性清洁剂用组合物,其中,
所述组合物进一步包含其他添加剂,
所述其他添加剂是赋形剂、崩解剂及润滑剂。
6.根据权利要求1所述的女性清洁剂用组合物,其中,
所述组合物是清洗组合物或阴道片。
7.根据权利要求1所述的女性清洁剂用组合物,其中,
所述组合物进一步包含第二天然萃取物,
所述第二天然萃取物选自由白芷萃取物、Seombadi萃取物及其混合物构成的组。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190086098A KR102224920B1 (ko) | 2019-07-17 | 2019-07-17 | 천연 추출물을 포함하는 여성 청결제용 조성물 |
KR10-2019-0086098 | 2019-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112237625A true CN112237625A (zh) | 2021-01-19 |
Family
ID=74170387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010206229.6A Pending CN112237625A (zh) | 2019-07-17 | 2020-03-23 | 包含天然萃取物的女性清洁剂用组合物 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102224920B1 (zh) |
CN (1) | CN112237625A (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101019954A (zh) * | 2007-03-13 | 2007-08-22 | 谷振江 | 生态洁阴抑菌液 |
CN101829041A (zh) * | 2010-04-30 | 2010-09-15 | 北京欧凯纳斯科技有限公司 | 一种杀菌止痒的妇科洗液 |
KR20110009869A (ko) * | 2009-07-23 | 2011-01-31 | 대전대학교 산학협력단 | 섬바디 추출물을 유효성분으로 함유하는 항아토피용 화장료 조성물 |
KR20120063076A (ko) * | 2010-12-07 | 2012-06-15 | (주)선바이오텍 | 질염의 예방 또는 치료에 효과가 있는 항균제 조성물과 이를 포함하는 여성용 청결제 조성물 |
KR20130016176A (ko) * | 2012-12-28 | 2013-02-14 | 제주대학교 산학협력단 | 어류의 세균성 병원균에 대한 항균 조성물 |
CN104606315A (zh) * | 2015-03-09 | 2015-05-13 | 李汶峰 | 一种治疗女性阴部奇痒的外用药方及其制作方法 |
CN106539750A (zh) * | 2016-10-25 | 2017-03-29 | 天津市人意恒农业科技有限公司 | 一种女性护理凝胶及其制备方法 |
KR20170077567A (ko) * | 2015-12-28 | 2017-07-06 | 주식회사 서울식연 | 시트러스 추출물 또는 자몽종자 추출물을 함유하는 항균 조성물, 및 이를 포함하는 애완동물 위생용 제제 |
CN108096396A (zh) * | 2018-03-07 | 2018-06-01 | 西安璀璨生物科技有限责任公司 | 一种用于阴道黏膜抑菌的中药凝胶组合物 |
KR101951733B1 (ko) * | 2017-10-11 | 2019-02-25 | (주)인벤티지랩 | 프로폴리스 및 천연 추출물을 포함하는 여성 청결제용 조성물 및 이의 제조 방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170085703A (ko) * | 2016-01-15 | 2017-07-25 | 울산과학대학교 산학협력단 | 천연식물 추출물을 유효성분으로 함유하는 구강내 항염 및 구취 제거용 조성물 |
KR20180009293A (ko) * | 2016-07-18 | 2018-01-26 | 이예진 | 줄풀을 주재료로 한 천연 한방 구강청결제 및 이의 제조방법 |
-
2019
- 2019-07-17 KR KR1020190086098A patent/KR102224920B1/ko active IP Right Grant
-
2020
- 2020-03-23 CN CN202010206229.6A patent/CN112237625A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101019954A (zh) * | 2007-03-13 | 2007-08-22 | 谷振江 | 生态洁阴抑菌液 |
KR20110009869A (ko) * | 2009-07-23 | 2011-01-31 | 대전대학교 산학협력단 | 섬바디 추출물을 유효성분으로 함유하는 항아토피용 화장료 조성물 |
CN101829041A (zh) * | 2010-04-30 | 2010-09-15 | 北京欧凯纳斯科技有限公司 | 一种杀菌止痒的妇科洗液 |
KR20120063076A (ko) * | 2010-12-07 | 2012-06-15 | (주)선바이오텍 | 질염의 예방 또는 치료에 효과가 있는 항균제 조성물과 이를 포함하는 여성용 청결제 조성물 |
KR20130016176A (ko) * | 2012-12-28 | 2013-02-14 | 제주대학교 산학협력단 | 어류의 세균성 병원균에 대한 항균 조성물 |
CN104606315A (zh) * | 2015-03-09 | 2015-05-13 | 李汶峰 | 一种治疗女性阴部奇痒的外用药方及其制作方法 |
KR20170077567A (ko) * | 2015-12-28 | 2017-07-06 | 주식회사 서울식연 | 시트러스 추출물 또는 자몽종자 추출물을 함유하는 항균 조성물, 및 이를 포함하는 애완동물 위생용 제제 |
CN106539750A (zh) * | 2016-10-25 | 2017-03-29 | 天津市人意恒农业科技有限公司 | 一种女性护理凝胶及其制备方法 |
KR101951733B1 (ko) * | 2017-10-11 | 2019-02-25 | (주)인벤티지랩 | 프로폴리스 및 천연 추출물을 포함하는 여성 청결제용 조성물 및 이의 제조 방법 |
CN108096396A (zh) * | 2018-03-07 | 2018-06-01 | 西安璀璨生物科技有限责任公司 | 一种用于阴道黏膜抑菌的中药凝胶组合物 |
Non-Patent Citations (2)
Title |
---|
庞丽纹等: "狼毒大戟生药提取物抑菌活性的初步研究", 内蒙古农业大学学报(自然科学版), vol. 33, no. 5, pages 253 - 256 * |
焦丽等: "中西医结合治疗霉菌性阴道炎疗效观察", 中国妇幼保健, vol. 23, no. 26, pages 3671 - 3672 * |
Also Published As
Publication number | Publication date |
---|---|
KR102224920B1 (ko) | 2021-03-10 |
KR20210010682A (ko) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101345709B1 (ko) | 질염의 예방 또는 치료에 효과가 있는 항균제 조성물과 이를 포함하는 여성용 청결제 조성물 | |
US20130108599A1 (en) | Herbal Vaginal Compositions | |
WO2008140200A1 (en) | External compositions for the skin | |
KR100960054B1 (ko) | 탈모방지 및 두피개선을 위한 두발 화장품 조성물 | |
CN110478477A (zh) | 一种促进女性生殖健康的中药生物制剂及其制备方法 | |
KR101951733B1 (ko) | 프로폴리스 및 천연 추출물을 포함하는 여성 청결제용 조성물 및 이의 제조 방법 | |
US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
KR20160015718A (ko) | 쇠비름 추출물 및 피톤치드를 함유하는 여성 청결제 | |
CN110613839A (zh) | 一种作用于女性生殖系统的中药生物制剂及其制备方法 | |
CN108685769A (zh) | 一种复方中药乌发防脱洗发水及其制备方法 | |
CN102697857B (zh) | 一种防治产褥感染的产妇巾药水及其制备方法 | |
CN109620879A (zh) | 一种清湿修复膏及其制备方法 | |
CN105943666B (zh) | 一种用于婴幼儿敏感肌肤护理的组合物及其制备方法 | |
EP3134099A1 (en) | Anti-candida compositions and uses thereof | |
CN110339249B (zh) | 一种用于痔疮肛裂的中药组合物及其制备方法和应用 | |
CN103721138B (zh) | 一种治疗酒糟鼻的中药外用制剂及其制备方法 | |
CN113616774B (zh) | 一种含植物干细胞的抑菌组合物、养护抑菌液及其制备方法 | |
KR102575660B1 (ko) | 항균 활성을 갖는 외용제용 조성물을 포함하는 여성 청결제 | |
KR101860426B1 (ko) | 황백 추출물을 이용한 피부냉감용 생약조성물 및 이의 제조방법과 이를 이용한 피부개선제품 | |
KR102413425B1 (ko) | 베타글루칸을 포함하는 여성 청결제용 조성물 및 이를 포함하는 진공 충진 앰플 | |
CN106176525B (zh) | 一种中草药植物沐浴露 | |
CN112237625A (zh) | 包含天然萃取物的女性清洁剂用组合物 | |
US7563464B1 (en) | Treatment of mucosal membranes utilizing phytoestrogen | |
CN113491765A (zh) | 含蜂胶及天然萃取物的女性清洁剂用组合物及其制备方法 | |
KR102245617B1 (ko) | 장미 추출물 및 지유 추출물을 포함하는 여성 청결제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |